This website uses cookies to provide you with the best experience. By using this site you agree to our use of cookies. Please read our cookie notice for more information.

« Back

ICON Reports Revenues Up 2% And Strong New Business Wins

July 27, 2010

DUBLIN, Jul 27, 2010 (BUSINESS WIRE) -- ICON (NASDAQ: ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the second quarter ended June 30, 2010.

Net revenues for the quarter were $224 million, representing a 2% increase over net revenues of $220 million for the same quarter last year. On a constant currency basis revenue grew by 3.1%. Year-to-date, net revenues were $443 million, representing a 1% increase over the same period last year.

Income from operations was $25.7 million or 11.5% of revenue, compared to $29.3 million (before one-time net charges) or 13.3% for the same quarter last year. Constant currency operating margin was 11.8%. Net income was $22.9 million or 38 cents per share on a diluted basis, compared to $22.8 million or 38 cents per share last year.

Year-to-date income from operations was $52.5 million, compared to $56.2 million (before one-time net charges) last year representing a margin of 11.8% in 2010 and a margin of 12.8% in 2009. Net income was $45.1 million or 74 cents per share, compared with $43.7 million or 73 cents per share last year.

Days sales outstanding, comprising accounts receivable and unbilled revenue less payments on account, were 30 days at June 30, 2010, compared to 33 days at December 31, 2009.

For the quarter ended June 30, 2010, cash provided from operating activities was $35 million and capital expenditure was $7.5 million. As a result, the company's net cash, amounted to $221 million at June 30, 2010, compared to net cash of $194 million at December 31, 2009.

"Overall, we are pleased with our second quarter," commented CEO Mr Peter Gray. "Our net booking of $320m was particularly satisfying, resulting in a strong book to bill of 1.4, and the growth in our backlog to $1.9 bn. However, we are not expecting revenue growth to respond quickly to these awards, and as a result we now anticipate that the outcome for 2010 will be at the lower end of the guidance range given in February".

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release contains certain non-GAAP financial measures, including non-GAAP operating and net income and non-GAAP diluted earnings per share. While non-GAAP financial measures are not superior to or a substitute for the comparable GAAP measures, ICON believes certain non-GAAP information is useful to investors for historical comparison purposes.

The company will hold its second quarter conference call today, July 27, 2010 at 9:00 EST [14:00 Ireland & UK]. This call and linked slide presentation can be accessed live from our website at http://www.iconplc.com. A recording will also be available on the website for 90 days following the call. In addition, a calendar of company events, including upcoming conference presentations, is available on our website, under "Investors". This calendar will be updated regularly.

The statements made in this Press Release may contain forward-looking statements that involve a number of risks and uncertainties. In addition to the matters described in this Press Release, the ability to maintain large client contracts or enter into new contracts, maintain client relationships and the ability to manage the opening of new offices, the integration of new business mergers and acquisitions, as well as other risks and uncertainties detailed from time to time in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, may affect the actual results achieved by ICON. ICON disclaims any intent or obligation to update these forward-looking statements.

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 71 locations in 39 countries and has approximately 7,500 employees. Further information is available at www.iconplc.com.

ICON plc
Consolidated Income Statements (Unaudited) (Before one time net charges)
Three and Six Months ended June 30, 2010 and June 30, 2009
(Dollars, in thousands, except share and per share data)
Three Months Ended Six Months Ended
June 30, June 30, June 30, June 30,
2010 2009 2010 2009
Gross Revenue 313,087 300,969 622,638 619,507
Reimbursable expenses 89,336 80,968 179,775 179,675
Net Revenue 223,751 220,001 442,863 439,832
Costs and expenses
Direct costs 130,869 125,146 262,187 249,314
Selling, general and administrative 58,923 58,010 111,217 119,268
Depreciation and amortization 8,281 7,526 17,003 15,016
Total costs and expenses 198,073 190,682 390,407 383,598
Income from operations 25,678 29,319 52,456 56,234
Net interest income /(expense) 61 (875) (131) (1,611)
Income before provision of income taxes 25,739 28,444 52,325 54,623
Provision for income taxes 2,866 5,687 7,253 10,922
Net income 22,873 22,757 45,072 43,701
Net income per ordinary share
Basic $0.38 $0.39 $0.76 $0.75
Diluted $0.38 $0.38 $0.74 $0.73
Weighted average number of ordinary shares
Basic 59,667,635 58,576,384 59,395,142 58,557,089
Diluted 60,768,374 59,674,939 60,557,687 59,716,244
ICON plc
Consolidated Income Statements (Unaudited) (US GAAP)
Three and Six Months ended June 30, 2010 and June 30, 2009
(Dollars, in thousands, except share and per share data)
Three Months Ended Six Months Ended
June 30, June 30, June 30, June 30,
2010 2009 2010 2009
Gross Revenue 313,087 300,969 622,638 619,507
Reimbursable expenses 89,336 80,968 179,775 179,675
Net Revenue 223,751 220,001 442,863 439,832
Costs and expenses
Direct costs 130,869 125,146 262,187 249,314
Selling, general and administrative 58,923 58,010 111,217 119,268
Depreciation and amortization 8,281 7,526 17,003 15,016
One off items 8,941 8,941
Total costs and expenses 198,073 199,623 390,407 392,539
Income from operations 25,678 20,378 52,456 47,293
Net interest income/(expense) 61 (875) (131) (1,611)
Income before provision of income taxes 25,739 19,503 52,325 45,682
Provision for income taxes 2,866 973 7,253 6,208
Net income 22,873 18,530 45,072 39,474
Net income per ordinary share
Basic $0.38 $0.32 $0.76 $0.67
Diluted $0.38 $0.31 $0.74 $0.66
Weighted average number of ordinary shares
Basic 59,667,635 58,576,384 59,395,142 58,557,089
Diluted 60,768,374 59,674,939 60,557,687 59,716,244
ICON plc
Summary Balance Sheet Data
June 30, 2010 and December 31, 2009
(Dollars, in thousands)
June 30, December 31,
2010 2009
(Unaudited) (Audited)
Net cash 220,762 194,028
Accounts receivable 157,303 191,924
Unbilled revenue 86,631 92,080
Payments on account (141,338) (165,198)
Total 102,596 118,806
Working Capital 280,122 235,906
Total Assets 882,356 908,398
Shareholder's Equity 598,127 572,246
Source: ICON plc
Contact: Investor Relations 1-888-381-7923 or
Ciaran Murray CFO + 353 1 291 2000
Brendan Brennan VP Corp FP&A +353 12912000

All at ICON.

http://www.iconplc.com

ICON/ICLR-F

SOURCE: ICON plc

ICON
Investor Relations 1-888-381-7923
or
Ciaran Murray Chief Financial Officer
+ 353 -1-291-2000
or
Brendan Brennan Corporate VP Corp FP&A
+ 353 -1-291-2000

Copyright Business Wire 2010



Search Investor